Cardior’s €64M B round to push first-in-class heart failure program into Phase II

With a large series B round in hand, Cardior can now push its first-in-class lead program through Phase II proof of concept to determine whether inhibiting miR-132 can really be the first disease-modifying therapy for heart failure.

Germany cardiovascular company Cardior Pharmaceuticals GmbH raised €64 million ($75 million) in a round led by new investor Inkef Capital. The company previously raised €15 million in a series A round in 2017...